An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)

Trial Profile

An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Atacicept (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ATAMS-ext; ATAMS-Extension
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top